Prof. Dr.-Ing. Tobias Knopp

Universitätsklinikum Hamburg-Eppendorf (UKE)
Sektion für Biomedizinische Bildgebung
Lottestraße 55
2ter Stock, Raum 209
22529 Hamburg
- Postanschrift -

Technische Universität Hamburg (TUHH)
Institut für Biomedizinische Bildgebung
Gebäude E, Raum 4.044
Am Schwarzenberg-Campus 3
21073 Hamburg

Tel.: 040 / 7410 56794
Fax: 040 / 7410 45811
E-Mail: t.knopp(at)
E-Mail: tobias.knopp(at)



  • Head of the Institute for Biomedical Imaging
  • Editor-in-chief of the International Journal on Magnetic Particle Imaging (IJMPI)

Consulting Hours

  • On appointment

Research Interests

  • Tomographic Imaging
  • Image Reconstruction
  • Signal- and Image Processing
  • Magnetic Particle Imaging

Curriculum Vitae

Tobias Knopp received his Diplom degree in computer science in 2007 and his PhD in 2010, both from the University of Lübeck with highest distinction. For his PHD on the tomographic imaging method Magnetic Particle Imaging (MPI) he was awarded with the Klee award from the DGBMT (VDE) in 2011. From 2010 until 2011 he led the MAPIT project at the University of Lübeck and published the first scientific book on MPI. In 2011 he joined Bruker Biospin to work on the first commercially available MPI system. From 2012 until 2014 he worked at Thorlabs in the field of Optical Coherence Tomography (OCT) as a software developer. In 2014 he has been appointed as Professor for experimental Biomedical Imaging at the University Medical Center Hamburg-Eppendorf and the Hamburg University of Technology.


Title: Encapsulation of new MPI tracer nanoparticles in the human red blood cells.
Written by: A. Antonelli, P. Szwargulski, E. Scarpa, C. Grüttner, L. Guidi, G. Ambrosi, T. Knopp, M. Magnani
in: <em>International Journal on Magnetic Particle Imaging</em>. (2020).
Volume: <strong>6</strong>. Number: (2),
on pages: 1-3
how published:
DOI: 10.18416/IJMPI.2020.2009001


Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.